The global neurological biomarkers market is experiencing robust growth, with projections indicating an expansion from USD 9.45 billion in 2024 to USD 31.82 billion by 2034, representing a compound annual growth rate (CAGR) of 12.91% over the next decade, according to a new report from Nova One Advisor.
This significant market expansion is primarily fueled by the increasing prevalence of neurological disorders worldwide, coupled with substantial technological advancements and growing research and development investments in the field.
Market Segmentation Insights
Biomarker Types
Proteomic biomarkers currently hold the largest market share at 30.49%, a dominance attributed to recent developments in reproducibility and sensitivity in instruments such as microarray technology and LC-MS/MS. Advancements in immunoassay-based single-molecule multiplexing and quantification are further propelling this segment's growth.
Meanwhile, digital biomarkers are expected to demonstrate the fastest growth rate during the forecast period. This emerging segment benefits from minimal expenses, optimized health management capabilities, and the ability to provide individualized remote caregiving—allowing physicians to deliver personalized care remotely.
Disease Applications
Alzheimer's disease applications led the market in 2024, driven by increasing awareness and disease prevalence, coupled with growing emphasis on early diagnosis and timely treatment. The expanding geriatric population, who are particularly susceptible to Alzheimer's disease, is expected to further propel this segment's growth.
The Parkinson's disease segment is anticipated to grow at the fastest rate over the projected period. This acceleration is attributed to intensifying R&D efforts in biomarkers that could provide new opportunities for disease therapeutics. Recent product launches have significantly enhanced the scope of potential drug targets, positioning neurological biomarkers to transform Parkinson's disease treatment approaches.
End-User Landscape
Research organizations and other related entities dominated the market with a 45.0% share in 2024. This leadership position stems from substantial funding provided by research organizations for biomarker discovery, assessment, and qualification across various neurological conditions.
The hospital and hospital laboratories segment is projected to exhibit the fastest growth during the study period. This growth is linked to rising global hospitalization rates and ongoing developments in healthcare infrastructure that are improving hospital facilities. Additionally, hospitals acquire and utilize a large quantity of blood-based biomarker assays, further driving segment expansion.
Regional Market Dynamics
North America: Sustained Leadership
North America accounted for a significant 42.0% revenue share in 2024 and is expected to maintain strong growth through 2034. The region's dominance can be attributed to increasing awareness regarding biomarkers' potential in drug development, presence of strong regulatory bodies, and continuous innovations in R&D by key market players.
Within North America, the United States leads the market, benefiting from the presence of major medical device players in neurobiology and well-established research and healthcare infrastructure. Notable developments include Quanterix Corporation's July 2023 launch of LucentAD, a blood biomarker test designed to aid in Alzheimer's disease diagnosis.
Asia Pacific: Emerging Growth Hub
The Asia Pacific region is projected to experience the fastest growth rate over the forecast period. This acceleration is driven by rising disposable income in emerging economies such as India and China, increasing incidence of neurological disorders, and a growing elderly population susceptible to these diseases.
Market Trends and Innovations
Several key trends are shaping the neurological biomarkers landscape:
Rising Cancer Prevalence
Biomarkers serve as vital indicators for many diseases and health traits. The complex carcinogenesis process in cancer, involving multiple events from different molecular pathways, makes prognosis, diagnosis, and therapy more complicated—creating greater demand for effective biomarkers.
Precision Medicine Advancements
Research associated with biomarkers in neurodegenerative conditions represents an emerging field in individualized medicine. The evolution of precision medicine has broadly impacted the medical and biopharmaceutical sectors, contributing to market expansion.
Artificial Intelligence Integration
Innovations in AI are transforming neurology, creating new avenues for timely detection of conditions that previously could only be identified in advanced stages. AI systems can recognize patterns in brainwaves that detect conditions like Multiple Sclerosis or Parkinson's disease, with key market players leveraging AI for brain image processing and developing medical tools for neurodegenerative conditions.
Recent Developments
The market has witnessed several significant developments:
-
In April 2024, the Bill & Melinda Gates Foundation awarded a $1.5 million grant to Owlstone Medical to develop breath-based diagnostics and detect breath biomarkers for tuberculosis and HIV.
-
In October 2023, C2N Diagnostics launched an advanced fluid biomarker targeting neurofibrillary "Tau" tangle pathology in Alzheimer's disease, providing researchers with a vital tool for monitoring disease progression.
-
In July 2023, Beckman Coulter Diagnostics and Fujirebio announced a partnership combining their immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in neurodegenerative diseases.
Key Market Players
The neurological biomarkers market features several prominent companies, including:
- Abbott
- Thermo Fisher Scientific, Inc.
- Merck & Co., Inc.
- Bio-Rad Laboratories, Inc.
- Johnson & Johnson Services, Inc.
- DiaGenic ASA
- Banyan Biomarkers, Inc.
- Quanterix
- Alseres Pharmaceuticals, Inc.
- Rules-Based Medicine
Blood-Based Biomarkers: A Parallel Growth Story
The broader blood-based biomarkers market is also experiencing significant growth, projected to expand from $18.8 billion in 2022 to approximately $49.24 billion by 2030, representing a CAGR of 12.8%, according to Coherent Market Insights.
This growth is driven by increasing adoption of personalized medicines, which help physicians determine appropriate treatments based on patients' genetic makeup and individual molecular profiles. Biomarkers play a crucial role in this process by identifying the right markers for various diseases.
Within this market, screening biomarkers account for approximately 35% of the total market share, helping in early disease detection during regular health checkups. Diagnostic biomarkers represent about 30% of the market, aiding in confirming disease presence, determining disease stage, and identifying genetic mutations.
Cancer biomarkers captured around 40% of the total market in 2023, reflecting the high incidence of various cancers and ongoing R&D for novel cancer biomarkers.
Market Outlook
The neurological biomarkers market is poised for continued expansion, driven by increasing disease prevalence, technological advancements, and growing investment in research and development. As precision medicine continues to evolve and AI integration accelerates, the market is expected to witness further innovations in biomarker discovery and application.
The growing emphasis on early disease detection and personalized treatment approaches will likely sustain market growth, particularly in regions with aging populations and rising healthcare expenditure. Additionally, partnerships between research organizations and biotech companies to develop advanced neurological treatments are expected to propel the market forward over the forecast period.
